Introduction {#sec0005}
============

The recent discovery and global dissemination of mobile genetic elements (*mcr*) that can confer colistin (polymyxin E) resistance have jeopardized the efficacy of this last resort antibiotic and raised public health concerns \[[@bib0005],[@bib0010]\]. The spread of *mcr* might be most problematic in countries with limited resources and developing antimicrobial stewardship \[[@bib0015]\]. Previously, we have described the use of colistin in medicine and agriculture and documented the prevalence of *mcr-1* in multidrug-resistant *Escherichia coli* in different matrices in Lebanon \[[@bib0020], [@bib0025], [@bib0030]\]. However, sources and transmission of *mcr* remain largely uncharacterized in Lebanon, especially in relation to the human population. Therefore, we initiated surveillance efforts in order to better understand the molecular epidemiology of *mcr* in Lebanon.

Case report {#sec0010}
===========

During routine screening of fecal matter collected from diapers of 2-year-old toddlers in the community, we identified whitish and irregularly shaped colonies on RAPID\'E.coli 2 agar supplemented with 4 μg/ml colistin \[[@bib0020], [@bib0025], [@bib0030]\]. A colony (LB-SH32) was further purified and appeared colorless and unable to ferment lactose on MacConkey agar but had distinctive "fishy" odor. PCR analysis showed that LB-SH32 was positive for a species-specific urease gene (*ureC*) fragment, which identified the isolate as *Proteus mirabilis* \[[@bib0035]\], a Gram-negative enteric bacterium that most commonly causes urinary tract infections but may also lead to respiratory tract-, wound- and other infections. Minimum inhibitory concentration (MIC) analysis showed that LB-SH32 was highly resistant to colistin (MIC \> 4096 μg/ml), indicating that the isolate was intrinsically colistin-resistant as expected for *P. mirabilis* \[[@bib0040]\]. However, the isolate was *mcr-1*-positive (*mcr-2* to *8*-negative), which was confirmed by commercial sequencing. Heat shock transformation with plasmids extracted from LB-SH32 resulted in the successful introduction of the *mcr*-*1* into chemically-competent *E. coli* JM109, indicating that the *mcr-1* was plasmid-borne and transmissible to other bacteria. The transformants were also resistant to colistin (MIC ≥ 8 μg/ml). Typing showed that the plasmids belonged to IncP1-alpha, which has a broad-host range, can transfer and replicate in different Gram-negative bacteria, and can transmit resistance genes \[[@bib0045],[@bib0050]\]. LB-SH32 was multidrug-resistant, displaying resistance to amoxicillin-calvulanic acid, cephalexin, imipenem, gentamicin, kanamycin, streptomycin, tetracycline, and trimethoprim-sulfamethoxazole, while harboring genes encoding beta-lactamase (*bla~TEM-1~*, *bla~NDM-1~*, *bla~KPC~*), tetracycline resistance (*tetA*, *B*, and *C*), sulfonamide resistance (*sul1* and *2*), Class-1 Integrons, and integrase (*int1*).

Discussion {#sec0015}
==========

This is the first report of 1) transmissible plasmid-borne *mcr-1* in *P. mirabilis* from humans and 2) the detection of *mcr-1* in the Lebanese population. During the peer-review assessment of this study, a manuscript reported the detection of *mcr-1* in six clinical *E. coli* isolates of human origins in Lebanon \[[@bib0055]\]. Also, as previously mentioned, our study targeted the Lebanese population at large and was conducted on the level of the community in a non-clinical setting. Because *P. mirabilis* is intrinsically colistin resistant, this pathogen is often not screened for *mcr*. However, our study shows that *P. mirabilis* can serve as reservoir for the transmission of these genes to colistin-susceptible bacteria. Therefore, the overlooked role of *P. mirabilis* might be important to further understand the epidemiology and dissemination of *mcr*.
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